Trials / Completed
CompletedNCT01357356
Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 750 (actual)
- Sponsor
- Serenity Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia for a total duration of 14 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SER120 (750 ng/day) | |
| DRUG | SER120 (1000 ng/day) | SER120 (1000 ng/day) |
| DRUG | SER120 (1500 ng/day) | |
| DRUG | Placebo |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2012-10-01
- Completion
- 2014-12-01
- First posted
- 2011-05-20
- Last updated
- 2020-10-08
- Results posted
- 2020-10-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01357356. Inclusion in this directory is not an endorsement.